Lorus Announces Presentation of Supportive Data for LOR-2040 in Acute Myeloid Leukemia
News Apr 24, 2009
Ohio State University Researchers Present Results from Clinical Sample Analysis at the 100th Annual Meeting of the American Association for Cancer Research (AACR).
Lorus Therapeutics Inc. has announced the presentation by investigators at Ohio State University (OSU) of results for Lorus' lead clinical drug candidate LOR-2040, formerly known as GTI-2040, at the 100th Annual Meeting of the AACR in Denver, CO, April 18-22, 2009.
The presentation entitled "In vitro-in vivo pharmacodynamic analysis of GTI-2040 combined with Ara-C in acute myeloid leukemia" was presented and the abstract for the presentation (Abstract Number: 5447) is available online on the AACR website.
In the presentation the study investigators reported their findings on the pharmacodynamics (drug effects) of LOR-2040 in combination with the chemotherapy drug Ara-C in Acute Myeloid Leukemia (AML).
The studies were done to provide additional support for this drug combination in the ongoing clinical program with R2-targeted drug LOR-2040, and included analysis of samples from relapsed/refractory AML patients treated with LOR-2040 and high dose Ara-C from a recently completed Phase Ib trial.
The results of the pharmacodynamic studies showed that R2 levels in leukemia cells were decreased following treatment with LOR-2040 alone or in combination with Ara-C that resulted in a significant decrease in levels of intracellular dNTPs, which are the products of R2 activity and the necessary building blocks for the synthesis of DNA and cell growth.
Furthermore, analysis of the bone marrow samples from AML patients treated with LOR-2040 and high-dose Ara-C showed that bone marrow samples with reduced levels of dNTPs had higher amounts of Ara-CTP, which is the cytotoxic product of Ara-C.
Based on their findings, the OSU investigators concluded that correlation of pharmacodynamic measures of LOR-2040 and Ara-C may be useful in assessing overall clinical response in AML.
"Our clinical strategy for AML is to combine Ara-C activity with R2 targeting by LOR-2040 to deliver a one-two punch to the cancer", said Dr. Aiping Young, Lorus' President and CEO. "We are pleased that the study results by our OSU collaborators support this combination strategy. We believe these findings help to strengthen our clinical program with LOR-2040 in relapsed/refractory AML".